General medicines
Product information:
- AVANDIA product monograph (PDF - 1,279 KB)
Patient Informed Consent Package:
- AVANDIA Patient Informed Consent Form (PDF - 221 KB)
- AVANDIA Consumer Information (PDF - 206 KB)
Health Care Professional Information:
- November 9, 2010 - Health Canada Endorsed Information on Important New Restrictions on the use of rosiglitazone (AVANDIA, AVANDAMET and AVANDARYL) (PDF - 457 KB)
- November 1, 2007 - Health Canada endorsed important safety information regarding AVANDIA, AVANDAMET and AVANDARYL (PDF - 451 KB)
- June 1, 2007 - Health Canada endorsed important safety information regarding AVANDIA and AVANDAMET (PDF - 489 KB)
- February 23, 2007 - Health Canada endorsed important safety information regarding AVANDIA and AVANDAMET (PDF - 83.7 KB)
- December 19, 2005 - Health Canada endorsed important safety information regarding AVANDIA and AVANDAMET (PDF - 63.5 KB)
- November 13, 2001 - Important safety information regarding AVANDIA (rosiglitazone maleate) (PDF - 65.0 KB)
Public Communications:
- November 18, 2010 - Health Canada Endorsed Information on Important New Restrictions on the use of rosiglitazone (AVANDIA, AVANDAMET and AVANDARYL) (PDF - 153 KB)
- November 6, 2007 - Health Canada endorsed important safety information regarding AVANDIA, AVANDAMET and AVANDARYL (PDF - 445 KB)
- May 30, 2007 - Health Canada endorsed important safety information on AVANDIA and AVANDAMET (PDF - 458 KB)
- February 28, 2007 - Health Canada endorsed important safety information on AVANDIA and AVANDAMET (PDF - 41.3 KB)
- December 20, 2005 - Health Canada endorsed important safety information on AVANDIA and AVANDAMET (PDF - 74.0 KB)
